Business Context and Reporting Period
This Form 8-K filing by GlycoMimetics, Inc. (not Crescent Biopharma, Inc.) was submitted on September 20, 2016. The report discloses a corporate governance event regarding the resignation of a director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial data.
Material Changes
The material change reported is the resignation of Franklin H. Top, Jr., M.D., from the Board of Directors. Dr. Top notified the board of his intention not to seek re-election. His term as a director will conclude at the 2017 Annual Meeting of Stockholders. Additionally, he will resign as Chairman of the Nominating and Corporate Governance Committee effective January 1, 2017, though he will remain a committee member until the end of his term.
Management Commentary and Risks
CEO Rachel K. King stated that the Board and the company wish to thank Dr. Top for his service, noting he was a founding board member whose guidance was invaluable. The filing does not disclose specific risks, contingencies, or unusual items beyond the standard departure of a director.
Key Facts for Investor Verification
- Franklin H. Top, Jr., M.D. is not seeking re-election as a director.
- Dr. Top's directorship ends at the 2017 Annual Meeting of Stockholders.
- Dr. Top will step down as Chairman of the Nominating and Corporate Governance Committee on January 1, 2017.
- The company is GlycoMimetics, Inc., not Crescent Biopharma, Inc.